Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cincinnati Financial Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Cincinnati Financial Corporation trades at $180.5 (market cap $27.73B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Cincinnati Financial Corporation pays a 2.1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CINF | |
|---|---|---|
Market Cap | $39.89B | $27.73B |
Sector | Health | Financials |
52-Week High | $491.22 | $192.03 |
52-Week Low | $278.09 | $145.80 |
Enterprise Value | $38.15B | $27.41B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CINF trades at $179.28, up 2.19% today, near its consensus price target of $185.75. The stock shows strong fundamentals with a P/E of 10.25, net income margin of 21.33%, and consistent earnings beats in recent quarters. Technical indicators are bearish overall, with the current price near the pivot point of $178. Recent news highlights a scheduled Q2 2026 earnings webcast and a 65-year dividend streak, with a $0.94 dividend paid in July 2026.
Outlook remains positive due to valuation appeal and earnings momentum, but risks include technical bearish signals and exposure to catastrophe losses. Revenue growth is steady, projected to reach $12.9B in 2026, supporting a bullish analyst consensus despite mixed technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
